Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 20/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 19/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 18/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 0.58 |
| ▸ | NCOR2 | Q9Y618 | 7/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.58 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.58 |
| ▸ | UBA1 | P22314 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15827017 | 0.90 | HDAC3 (0.70) | HDAC3HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL71104 | 0.90 | HDAC3 (0.70) | HDAC3HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL12610955 | 0.87 | HDAC3 (0.60) | HDAC3HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL15827014 | 0.86 | HDAC3 (0.76) | HDAC3HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL15827018 | 0.86 | HDAC3 (0.64) | HDAC3HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL18220759 | 0.84 | HDAC3 (0.81) | HDAC3HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL18477564 | 0.82 | HDAC1 (0.54) | HDAC3HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL13453159 | 0.82 | HDAC1 (0.74) | HDAC3HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL18477570 | 0.82 | HDAC1 (0.70) | HDAC3HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL15827015 | 0.82 | HDAC3 (0.52) | HDAC3HDAC1HDAC2HDAC6HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170035759-A1 | TREATMENT OF PARASITIC DISEASES USING KDAC INHIBITOR COMPOUNDS | WASHINGTON UNIVERSITY (US) | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170035759-A1 | TREATMENT OF PARASITIC DISEASES USING KDAC INHIBITOR COMPOUNDS | HSP90B1, TBCA, RPL17 | HDAC3 542/4885HDAC1 443/4885HDAC2 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.